Send us a text

In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the remarkable and controversial story of Gilead Sciences, a company that redefined what medicine could achieve. From its beginnings in the late 1980s under physician-scientist Michael Riordan, Gilead transformed antiviral drug development with breakthroughs in HIV treatment, revolutionized global health with a cure for hepatitis C, and pushed into oncology with cutting-edge CAR-T therapies.

But alongside these triumphs came firestorms of criticism, from the $84,000 price tag of Sovaldi to debates around HIV drug access and patents. Gilead has long walked the fine line between lifesaving innovation and public outrage, forcing society to wrestle with the question: What is the true price of a cure?

Join us as we unpack Gilead’s origins, its blockbuster breakthroughs, its controversies, and what lies ahead for one of biotech’s most influential and polarizing companies.

Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#Biotech #GileadSciences #HIV #HepatitisC #CART #Oncology #DrugDiscovery #Pharma #HealthcareInnovation #MedicalBreakthroughs #PetriDishPerspectives

Support the show

© 2025 Petri Dish Perspectives LLC. All rights reserved.